Clinical Trial

Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma

Name: Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma — clinical trial record (NCT07600151)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CONQUISTADOR

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.

Trial Details

NCT Number	NCT07600151
Lead Sponsor	Universitätsklinikum Hamburg-Eppendorf Collaborators: AbbVie, Sanofi
Conditions	Myeloma Multiple, Myeloma
Enrollment	220 participants
Start Date	2026-12-01
Primary Completion	2036-09-30 (estimated)
Study Completion	2036-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-20